Innate immune regulatory networks in hepatic lipid metabolism
- PMID: 30891617
- DOI: 10.1007/s00109-019-01765-1
Innate immune regulatory networks in hepatic lipid metabolism
Abstract
Hepatic lipid metabolism is closely associated with certain diseases, such as obesity, diabetes, fatty liver, and hepatic fibrosis. Hepatic steatosis results from systemic metabolic dysfunction that occurs via multiple processes. The initial process has been characterized as hepatic lipid accumulation that may be caused by increased liver lipid uptake and de novo lipogenesis or decreased lipid oxidation and lipid export; subsequently, multiple additional factors that trigger inflammation and insulin resistance (IR) aggravate the progression of hepatic steatosis. Emerging evidence indicates that inflammation stands at the crossroads of innate immunity and lipid metabolism and links the initial metabolic stress and subsequent metabolic events in lipid metabolism. Therefore, in this review, we summarize the regulatory role of innate immune signaling molecules in maintaining lipid metabolic homeostasis; these revelations can guide the development of potential therapies for nonalcoholic fatty liver disease (NAFLD).
Keywords: Inflammation; Innate immunity; Insulin resistance; Lipid metabolism; NAFLD.
Similar articles
-
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.J Endocrinol. 2017 Jul;234(1):R1-R21. doi: 10.1530/JOE-16-0513. Epub 2017 Apr 20. J Endocrinol. 2017. PMID: 28428362 Review.
-
FBXW7 suppresses HMGB1-mediated innate immune signaling to attenuate hepatic inflammation and insulin resistance in a mouse model of nonalcoholic fatty liver disease.Mol Med. 2019 Jun 18;25(1):29. doi: 10.1186/s10020-019-0099-9. Mol Med. 2019. PMID: 31215394 Free PMC article.
-
Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease.Trends Endocrinol Metab. 2019 Dec;30(12):903-914. doi: 10.1016/j.tem.2019.08.006. Epub 2019 Oct 6. Trends Endocrinol Metab. 2019. PMID: 31597607 Review.
-
'Micro-managers' of hepatic lipid metabolism and NAFLD.Wiley Interdiscip Rev RNA. 2015 Sep-Oct;6(5):581-93. doi: 10.1002/wrna.1295. Epub 2015 Jul 21. Wiley Interdiscip Rev RNA. 2015. PMID: 26198708 Review.
-
Role of Innate Immune Signaling in Non-Alcoholic Fatty Liver Disease.Trends Endocrinol Metab. 2018 Oct;29(10):712-722. doi: 10.1016/j.tem.2018.08.003. Epub 2018 Aug 18. Trends Endocrinol Metab. 2018. PMID: 30131212 Review.
Cited by
-
Ubiquitination and Metabolic Disease.Adv Exp Med Biol. 2024;1466:47-79. doi: 10.1007/978-981-97-7288-9_4. Adv Exp Med Biol. 2024. PMID: 39546135 Review.
-
Liver Fibrosis and MAFLD: From Molecular Aspects to Novel Pharmacological Strategies.Front Med (Lausanne). 2021 Oct 22;8:761538. doi: 10.3389/fmed.2021.761538. eCollection 2021. Front Med (Lausanne). 2021. PMID: 34746195 Free PMC article. Review.
-
Correlation between the triglyceride-glucose index and the onset of atrial fibrillation in patients with non-alcoholic fatty liver disease.Diabetol Metab Syndr. 2023 May 9;15(1):94. doi: 10.1186/s13098-023-01012-1. Diabetol Metab Syndr. 2023. PMID: 37158953 Free PMC article.
-
Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests.Int J Mol Sci. 2021 Jul 19;22(14):7702. doi: 10.3390/ijms22147702. Int J Mol Sci. 2021. PMID: 34299321 Free PMC article. Review.
-
Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies?Int J Mol Sci. 2021 May 20;22(10):5375. doi: 10.3390/ijms22105375. Int J Mol Sci. 2021. PMID: 34065331 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical